CDK2


Also found in: Medical.
AcronymDefinition
CDK2Cyclin-Dependent Kinase 2
References in periodicals archive ?
16) Recent work in our laboratory has shown that in a transgenic PKD2 rat model, the mutant PC-2 (PKD2 [1-703]) induces proliferation in primary tubular epithelial cells in a STAT1/p21 independent fashion and is accompanied by alteration in expression of the cyclin dependent kinase inhibitor p57 and the Cdk2.
In order to progress through S-phase, CDK2 and CDK1 need to be assembled with cyclin A and cyclin B.
The labelling index of skp2 in endometrial carcinoma was significantly correlated with that of p27, Ki-67, cdk2, cyclin A, cyclin D1, cyclin E, p53 and PTEN.
More necently, erythrosin B (dose range: 25-100 [micro]g/mL) has been shown to stimulate proliferation in estrogen receptor (ER) positive HTB 133 cells and to increase Cdk2 activity (dose range: 3-10 [micro]g/mL) in MCF7 cells (Dees et al.
Morgan and Sung-Hou Kim of the University of California at Berkeley had previously determined the structure of CDK2.
CDK2 is activated by cyclin A subunits, and cyclin A is critical for cell cycle control, primarily in the Gl and S phases (Furuno et al.
3] induces p27, inhibiting CDK2 activity, phosphorylation of retinoblastoma protein, and inhibition of DNA synthesis.
These data (Abstract #4972) were presented during a minisymposium on Novel Genomic Approaches, Drugs, Targets, and Strategies in a talk titled "SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates preclinical activity in human multiple myeloma.
P21 inhibits kinase activity and blocks progression through G1 IS by association with CDK2 complexes (Lo et al.
SNS-032 Oral Presentation Tuesday, April 15, 2008 -- SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates preclinical activity in human multiple myeloma Minisymposium: Novel Genomic Approaches, Drugs, Targets, and Strategies Abstract #4972 4:55 p.